StockCIK 1703057

AbCellera Biologics Inc. (ABCL): Insider Trades and Fund Holdings

In the past 12 months, AbCellera Biologics Inc. insiders reported 4 open-market purchases worth $1.55M and 0 sales worth $0.

4Insider buys, 12 months

$1.55MBought by insiders, 12 months

$0Sold by insiders, 12 months

1Tracked funds holding

Recent insider trades

Open-market purchases (code P) and sales (code S) from Form 4. Grants, option exercises and gifts are not shown. Latest filing: Aug 24, 2026.

Recent ABCL insider trades
Filed	Traded	Insider	Role	Type	Shares	Price ($)	Value	Holding	Filing
Aug 24	Aug 24	Michael R. HaydenDirector	Director (ind.)	▲ BUY	53,613	10.64	$570K	+4.1%	Form 4 ↗
Aug 18	Aug 18	John S. MontalbanoDirector	Director	▲ BUY	10,000	11.03	$110K	+4.1%	Form 4 ↗
Aug 14	Aug 12	Michael R. HaydenDirector	Director (ind.)	▲ BUY	46,387	10.37	$481K	+3.6%	Form 4 ↗
Aug 14	Aug 14	Andrew BoothCFO	CFO	▲ BUY	37,200	10.32	$384K	+8.3%	Form 4 ↗

Source: SEC Form 4 filings, retrieved Oct 28, 2026. How we read filings

Insiders who traded in the past year

Insider	Role	Buys	Bought	Sold	Latest
Michael R. Hayden	Director	2	$1.05M	$0	Aug 24, 2026
John S. Montalbano	Director	1	$110K	$0	Aug 18, 2026
Andrew Booth	CFO	1	$384K	$0	Aug 14, 2026

Tracked funds that report ABCL

From each fund's latest 13F. Holdings are as of quarter end and are filed up to 45 days later.

Fund	Quarter	Shares	Value	% of portfolio	Change
Renaissance Technologies	Q2 2026	990,929	$7.78M	0.01%	▼ −34.4%

Source: SEC Form 13F-HR filings, retrieved Oct 28, 2026. How we read filings

Reading these numbers

Insiders sell for many reasons: taxes, diversification, a house. Purchases with their own money are rarer and are usually read as more informative. A Form 4 is due within two business days of the trade. How to read a Form 4 →